-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PK-101 in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PK-101 in Osteoarthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PK-101 in Osteoarthritis Drug Details: PK-101, a fixed dose combination of PK101-001 and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Neuroendocrine Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Neuroendocrine Tumors Drug Details: Nedisertib (M-3814, MSC-2490484A) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Non-Small Cell Lung Cancer Drug Details: Nedisertib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Metastatic Renal Cell Carcinoma Drug Details: Nedisertib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Solid Tumor Drug Details: Nedisertib (M-3814, MSC-2490484A) is under...
-
Product Insights
Rheumatic Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Rheumatic Disorders - Drugs In Development, 2023’, provides an overview of the Rheumatic Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rheumatic Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-901 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-901 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-901 in Solid Tumor Drug Details: SL-901 is under development for the...
-
Sector Analysis
Liechtenstein Insurance Industry – Key Trends and Opportunities to 2027
Liechtenstein Insurance Market Report Overview The gross written premium of the Liechtenstein insurance market was CHF5.5 billion ($5.8 billion) in 2022. The market is expected to achieve a CAGR of more than 3% during 2023-2027. The Liechtenstein insurance market research report provides in-depth market analysis, information, and insights into the Liechtenstein insurance industry. It provides a detailed outlook by product category as well as values for key performance indicators such as gross written premium, penetration, premium accepted and ceded, profitability...